Cowealth Medical China Co.Ltd. (603122) - Total Liabilities

Latest as of March 2026: CN¥367.76 Million CNY ≈ $53.81 Million USD

Based on the latest financial reports, Cowealth Medical China Co.Ltd. (603122) has total liabilities worth CN¥367.76 Million CNY (≈ $53.81 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 603122 cash flow conversion to assess how effectively this company generates cash.

Cowealth Medical China Co.Ltd. - Total Liabilities Trend (2019–2025)

This chart illustrates how Cowealth Medical China Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check 603122 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Cowealth Medical China Co.Ltd. Competitors by Total Liabilities

The table below lists competitors of Cowealth Medical China Co.Ltd. ranked by their total liabilities.

Company Country Total Liabilities
Tatwah Smartech Co Ltd
SHE:002512
China CN¥1.89 Billion
Jinxi Axle Co Ltd
SHG:600495
China CN¥760.99 Million
Kuros Biosciences AG
SW:KURN
Switzerland CHF40.28 Million
Prima Andalan Mandiri Tbk PT
JK:MCOL
Indonesia Rp158.96 Million
ZYLOX-TONBRDG.MED.TECH.H1
F:818
Germany €341.97 Million
Nuh Cimento Sanayi AS
IS:NUHCM
Turkey TL4.16 Billion
Daewon Cable Co. Ltd. Preference Shares
KO:006345
Korea ₩174.33 Billion

Liability Composition Analysis (2019–2025)

This chart breaks down Cowealth Medical China Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cowealth Medical China Co.Ltd. market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.05 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.35 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.26 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cowealth Medical China Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cowealth Medical China Co.Ltd. (2019–2025)

The table below shows the annual total liabilities of Cowealth Medical China Co.Ltd. from 2019 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥368.90 Million
≈ $53.98 Million
+15.48%
2024-12-31 CN¥319.44 Million
≈ $46.74 Million
+9.21%
2023-12-31 CN¥292.49 Million
≈ $42.80 Million
-23.13%
2022-12-31 CN¥380.49 Million
≈ $55.68 Million
+17.15%
2021-12-31 CN¥324.78 Million
≈ $47.53 Million
-17.76%
2020-12-31 CN¥394.94 Million
≈ $57.79 Million
+15.93%
2019-12-31 CN¥340.68 Million
≈ $49.85 Million
--

About Cowealth Medical China Co.Ltd.

SHG:603122 China Diagnostics & Research
Market Cap
$757.80 Million
CN¥5.18 Billion CNY
Market Cap Rank
#10525 Global
#3001 in China
Share Price
CN¥13.01
Change (1 day)
-1.81%
52-Week Range
CN¥6.28 - CN¥30.01
All Time High
CN¥30.01
About

Cowealth Medical China Co.,Ltd. operates as a medical company in China. It offers centralized procurement services for in-vitro diagnostic reagents and consumables; platform for decision-making and analysis, commercialization of achievements in medical science and technology; a multi-channel coaxial time audio video imaging platform; and an AI-assisted system for clinical diagnosis. The company w… Read more